D'Apolito M, Guarnieri V, Boncristiano M, Zelante L, Savoia A (March 2002). "Cloning of the murine non-muscle myosin heavy chain IIA gene ortholog of human MYH9 responsible for May-Hegglin, Sebastian, Fechtner, and Epstein syndromes". Gene. 286 (2): 215–22. doi:10.1016/S0378-1119(02)00455-9. PMID11943476.
Eddinger TJ, Meer DP (August 2007). "Myosin II isoforms in smooth muscle: heterogeneity and function". American Journal of Physiology. Cell Physiology. 293 (2): C493–508. doi:10.1152/ajpcell.00131.2007. PMID17475667. S2CID9024520.
Li ZH, Bresnick AR (May 2006). "The S100A4 metastasis factor regulates cellular motility via a direct interaction with myosin-IIA". Cancer Research. 66 (10): 5173–80. doi:10.1158/0008-5472.CAN-05-3087. PMID16707441.
Kelley MJ, Jawien W, Ortel TL, Korczak JF (September 2000). "Mutation of MYH9, encoding non-muscle myosin heavy chain A, in May-Hegglin anomaly". Nature Genetics. 26 (1): 106–8. doi:10.1038/79069. PMID10973260. S2CID47565254.
Seri M, Cusano R, Gangarossa S, Caridi G, Bordo D, Lo Nigro C, et al. (September 2000). "Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes. The May-Heggllin/Fechtner Syndrome Consortium". Nature Genetics. 26 (1): 103–5. doi:10.1038/79063. PMID10973259. S2CID34477122.
Verver EJ, Topsakal V, Kunst HP, Huygen PL, Heller PG, Pujol-Moix N, et al. (January 2016). "Nonmuscle Myosin Heavy Chain IIA Mutation Predicts Severity and Progression of Sensorineural Hearing Loss in Patients With MYH9-Related Disease". Ear and Hearing. 37 (1): 112–20. doi:10.1097/AUD.0000000000000198. hdl:11336/43541. PMID26226608. S2CID27310678.
Savoia A, De Rocco D, Panza E, Bozzi V, Scandellari R, Loffredo G, et al. (April 2010). "Heavy chain myosin 9-related disease (MYH9 -RD): neutrophil inclusions of myosin-9 as a pathognomonic sign of the disorder". Thrombosis and Haemostasis. 103 (4): 826–32. doi:10.1160/TH09-08-0593. hdl:11336/15532. PMID20174760. S2CID3819344.
Kitamura K, Yoshida K, Shiraishi Y, Chiba K, Tanaka H, Furukawa K, et al. (November 2013). "Normal neutrophil myosin IIA localization in an immunofluorescence analysis can rule out MYH9 disorders". Journal of Thrombosis and Haemostasis. 11 (11): 2071–3. doi:10.1111/jth.12406. PMID24106837. S2CID32839438.
Kunishima S, Takaki K, Ito Y, Saito H (April 2009). "Germinal mosaicism in MYH9 disorders: a family with two affected siblings of normal parents". British Journal of Haematology. 145 (2): 260–2. doi:10.1111/j.1365-2141.2009.07584.x. PMID19208103. S2CID205265342.
Kunishima S, Yoshinari M, Nishio H, Ida K, Miura T, Matsushita T, et al. (March 2007). "Haematological characteristics of MYH9 disorders due to MYH9 R702 mutations". European Journal of Haematology. 78 (3): 220–6. doi:10.1111/j.1600-0609.2006.00806.x. PMID17241369. S2CID22638636.
Kas SM, de Ruiter JR, Schipper K, Annunziato S, Schut E, Klarenbeek S, et al. (August 2017). "Insertional mutagenesis identifies drivers of a novel oncogenic pathway in invasive lobular breast carcinoma". Nature Genetics. 49 (8): 1219–1230. doi:10.1038/ng.3905. PMID28650484. S2CID3255229.
Kim SJ, Lee S, Park HJ, Kang TH, Sagong B, Baek JI, et al. (October 2016). "Genetic association of MYH genes with hereditary hearing loss in Korea". Gene. 591 (1): 177–82. doi:10.1016/j.gene.2016.07.011. PMID27393652.
England K, Ashford D, Kidd D, Rumsby M (June 2002). "PKC epsilon is associated with myosin IIA and actin in fibroblasts". Cellular Signalling. 14 (6): 529–36. doi:10.1016/S0898-6568(01)00277-7. PMID11897493.
Verver EJ, Topsakal V, Kunst HP, Huygen PL, Heller PG, Pujol-Moix N, et al. (January 2016). "Nonmuscle Myosin Heavy Chain IIA Mutation Predicts Severity and Progression of Sensorineural Hearing Loss in Patients With MYH9-Related Disease". Ear and Hearing. 37 (1): 112–20. doi:10.1097/AUD.0000000000000198. hdl:11336/43541. PMID26226608. S2CID27310678.
Savoia A, De Rocco D, Panza E, Bozzi V, Scandellari R, Loffredo G, et al. (April 2010). "Heavy chain myosin 9-related disease (MYH9 -RD): neutrophil inclusions of myosin-9 as a pathognomonic sign of the disorder". Thrombosis and Haemostasis. 103 (4): 826–32. doi:10.1160/TH09-08-0593. hdl:11336/15532. PMID20174760. S2CID3819344.
D'Apolito M, Guarnieri V, Boncristiano M, Zelante L, Savoia A (March 2002). "Cloning of the murine non-muscle myosin heavy chain IIA gene ortholog of human MYH9 responsible for May-Hegglin, Sebastian, Fechtner, and Epstein syndromes". Gene. 286 (2): 215–22. doi:10.1016/S0378-1119(02)00455-9. PMID11943476.
Eddinger TJ, Meer DP (August 2007). "Myosin II isoforms in smooth muscle: heterogeneity and function". American Journal of Physiology. Cell Physiology. 293 (2): C493–508. doi:10.1152/ajpcell.00131.2007. PMID17475667. S2CID9024520.
Li ZH, Bresnick AR (May 2006). "The S100A4 metastasis factor regulates cellular motility via a direct interaction with myosin-IIA". Cancer Research. 66 (10): 5173–80. doi:10.1158/0008-5472.CAN-05-3087. PMID16707441.
Kelley MJ, Jawien W, Ortel TL, Korczak JF (September 2000). "Mutation of MYH9, encoding non-muscle myosin heavy chain A, in May-Hegglin anomaly". Nature Genetics. 26 (1): 106–8. doi:10.1038/79069. PMID10973260. S2CID47565254.
Seri M, Cusano R, Gangarossa S, Caridi G, Bordo D, Lo Nigro C, et al. (September 2000). "Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes. The May-Heggllin/Fechtner Syndrome Consortium". Nature Genetics. 26 (1): 103–5. doi:10.1038/79063. PMID10973259. S2CID34477122.
Savoia A, Pecci A (1993). "MYH9-Related Disease". In Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJ, Stephens K, Amemiya A (eds.). GeneReviews®. Seattle (WA): University of Washington, Seattle. PMID20301740.
Verver EJ, Topsakal V, Kunst HP, Huygen PL, Heller PG, Pujol-Moix N, et al. (January 2016). "Nonmuscle Myosin Heavy Chain IIA Mutation Predicts Severity and Progression of Sensorineural Hearing Loss in Patients With MYH9-Related Disease". Ear and Hearing. 37 (1): 112–20. doi:10.1097/AUD.0000000000000198. hdl:11336/43541. PMID26226608. S2CID27310678.
Savoia A, De Rocco D, Panza E, Bozzi V, Scandellari R, Loffredo G, et al. (April 2010). "Heavy chain myosin 9-related disease (MYH9 -RD): neutrophil inclusions of myosin-9 as a pathognomonic sign of the disorder". Thrombosis and Haemostasis. 103 (4): 826–32. doi:10.1160/TH09-08-0593. hdl:11336/15532. PMID20174760. S2CID3819344.
Kitamura K, Yoshida K, Shiraishi Y, Chiba K, Tanaka H, Furukawa K, et al. (November 2013). "Normal neutrophil myosin IIA localization in an immunofluorescence analysis can rule out MYH9 disorders". Journal of Thrombosis and Haemostasis. 11 (11): 2071–3. doi:10.1111/jth.12406. PMID24106837. S2CID32839438.
Kunishima S, Takaki K, Ito Y, Saito H (April 2009). "Germinal mosaicism in MYH9 disorders: a family with two affected siblings of normal parents". British Journal of Haematology. 145 (2): 260–2. doi:10.1111/j.1365-2141.2009.07584.x. PMID19208103. S2CID205265342.
Kunishima S, Yoshinari M, Nishio H, Ida K, Miura T, Matsushita T, et al. (March 2007). "Haematological characteristics of MYH9 disorders due to MYH9 R702 mutations". European Journal of Haematology. 78 (3): 220–6. doi:10.1111/j.1600-0609.2006.00806.x. PMID17241369. S2CID22638636.
Kas SM, de Ruiter JR, Schipper K, Annunziato S, Schut E, Klarenbeek S, et al. (August 2017). "Insertional mutagenesis identifies drivers of a novel oncogenic pathway in invasive lobular breast carcinoma". Nature Genetics. 49 (8): 1219–1230. doi:10.1038/ng.3905. PMID28650484. S2CID3255229.
Kim SJ, Lee S, Park HJ, Kang TH, Sagong B, Baek JI, et al. (October 2016). "Genetic association of MYH genes with hereditary hearing loss in Korea". Gene. 591 (1): 177–82. doi:10.1016/j.gene.2016.07.011. PMID27393652.
England K, Ashford D, Kidd D, Rumsby M (June 2002). "PKC epsilon is associated with myosin IIA and actin in fibroblasts". Cellular Signalling. 14 (6): 529–36. doi:10.1016/S0898-6568(01)00277-7. PMID11897493.
ncbi.nlm.nih.gov
"Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
"Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
Savoia A, Pecci A (1993). "MYH9-Related Disease". In Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJ, Stephens K, Amemiya A (eds.). GeneReviews®. Seattle (WA): University of Washington, Seattle. PMID20301740.
Eddinger TJ, Meer DP (August 2007). "Myosin II isoforms in smooth muscle: heterogeneity and function". American Journal of Physiology. Cell Physiology. 293 (2): C493–508. doi:10.1152/ajpcell.00131.2007. PMID17475667. S2CID9024520.
Kelley MJ, Jawien W, Ortel TL, Korczak JF (September 2000). "Mutation of MYH9, encoding non-muscle myosin heavy chain A, in May-Hegglin anomaly". Nature Genetics. 26 (1): 106–8. doi:10.1038/79069. PMID10973260. S2CID47565254.
Seri M, Cusano R, Gangarossa S, Caridi G, Bordo D, Lo Nigro C, et al. (September 2000). "Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes. The May-Heggllin/Fechtner Syndrome Consortium". Nature Genetics. 26 (1): 103–5. doi:10.1038/79063. PMID10973259. S2CID34477122.
Verver EJ, Topsakal V, Kunst HP, Huygen PL, Heller PG, Pujol-Moix N, et al. (January 2016). "Nonmuscle Myosin Heavy Chain IIA Mutation Predicts Severity and Progression of Sensorineural Hearing Loss in Patients With MYH9-Related Disease". Ear and Hearing. 37 (1): 112–20. doi:10.1097/AUD.0000000000000198. hdl:11336/43541. PMID26226608. S2CID27310678.
Savoia A, De Rocco D, Panza E, Bozzi V, Scandellari R, Loffredo G, et al. (April 2010). "Heavy chain myosin 9-related disease (MYH9 -RD): neutrophil inclusions of myosin-9 as a pathognomonic sign of the disorder". Thrombosis and Haemostasis. 103 (4): 826–32. doi:10.1160/TH09-08-0593. hdl:11336/15532. PMID20174760. S2CID3819344.
Kitamura K, Yoshida K, Shiraishi Y, Chiba K, Tanaka H, Furukawa K, et al. (November 2013). "Normal neutrophil myosin IIA localization in an immunofluorescence analysis can rule out MYH9 disorders". Journal of Thrombosis and Haemostasis. 11 (11): 2071–3. doi:10.1111/jth.12406. PMID24106837. S2CID32839438.
Kunishima S, Takaki K, Ito Y, Saito H (April 2009). "Germinal mosaicism in MYH9 disorders: a family with two affected siblings of normal parents". British Journal of Haematology. 145 (2): 260–2. doi:10.1111/j.1365-2141.2009.07584.x. PMID19208103. S2CID205265342.
Kunishima S, Yoshinari M, Nishio H, Ida K, Miura T, Matsushita T, et al. (March 2007). "Haematological characteristics of MYH9 disorders due to MYH9 R702 mutations". European Journal of Haematology. 78 (3): 220–6. doi:10.1111/j.1600-0609.2006.00806.x. PMID17241369. S2CID22638636.
Kas SM, de Ruiter JR, Schipper K, Annunziato S, Schut E, Klarenbeek S, et al. (August 2017). "Insertional mutagenesis identifies drivers of a novel oncogenic pathway in invasive lobular breast carcinoma". Nature Genetics. 49 (8): 1219–1230. doi:10.1038/ng.3905. PMID28650484. S2CID3255229.